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doi:10.1016/j.ejvs.2009.01.007Abstract Objective: Tissue-engineered blood vessels (TEBVs) represent an innovative
approach for overcoming reconstructive problems associated with extended vascular diseases
by providing small-calibre vascular grafts. This study aimed to evaluate a novel biomaterial of
bacterially synthesised cellulose (BC) as a potential scaffold for TEBV.
Methods: Highly crystalline cellulose was produced by a bacterium (Acetobacter xylinum)
using glucose as a source of carbon. Using a patented process, hollow-shaped segments of
BC were created with a length of 10 mm, an inner diameter of 3.0e3.7 mm and a wall thickness
of 0.6e1.0 mm. These grafts were used to replace the carotid arteries of eight pigs, and after
a follow-up period of 3 months, the grafts were removed and analysed, both macro- and micro-
scopically.
Results: Seven grafts (87.5%) remained patent, whereas one graft was found to be occluded.
Scanning electron microscopic examination revealed rapid re-cellularisation by recipient endo-
thelial cells. Light microscopic examination showed a three-layered wall structure of the BC
segments, with cellulose still being present in the media.
Conclusion: These data indicate that the innovative BC-engineering technique results in the
production of stable vascular conduits, which exhibit attractive properties for their use in
future TEBV programmes for vascular surgery.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.1 478 3180; fax: þ49 221 478
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ty for Vascular Surgery. PublisheAtherosclerotic vascular diseases, such as coronary artery
disease and peripheral vascular disease, are still the largest
cause of mortality in Western societies.1 Surgical treatment
of atherosclerosis began in 1952, when Voorhees et al.
proposed to replace diseased blood vessels with syntheticd by Elsevier Ltd. All rights reserved.
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(polyethylene terephthalate (PET)) and Teflon (expanded
polytetra-fluoroethylene (ePTFE)) grafts in vascular
surgery. However, these synthetic materials are clinically
unacceptable for reconstructing small-diameter arteries
(i.e., <6 mm, which are required in lower extremity bypass
and coronary artery bypass-grafting procedures), because
they are foreign bodies and thrombosis can occur on the
luminal surface, resulting in occlusion. For such small
artery bypass-grafting procedures, autologous arterial or
venous grafts still remain the most ideal vascular substi-
tutes. However, they cannot always be used because of
their poor quality and inadequate size or length. Moreover,
a second surgical procedure is required to obtain the
vessel. Thus, it is imperative to develop innovative tech-
nologies targeting the fabrication of small-calibre vascular
grafts. The concept of tissue engineering using biodegrad-
able materials was proposed recently,3 and such materials
have been developed and applied clinically with autologous
cell seeding or bioreactor culture.4e6 However, the utility
of these materials in the reconstruction of small-calibre
vascular grafts has not been demonstrated. Moreover, pre-
treatment with autologous cell seeding or bioreactor
culture can be complicated and invasive and will render the
graft susceptible to infection.
Bacterial cellulose (BC) is a polysaccharide that is
excreted extracellularly by the Acetobacter xylinum
bacteria as long non-aggregated nanofibrils. BC displays
many unique properties, including high mechanical
strength, water content, crystallinity as well as an ultra-
fine, highly pure, nanofibril network structure.7 A. xylinum
constructs a pellicle of BC that has a dense outer surface
and a gelatinous layer inner surface. BC has been used in
a microvessel endoprothesis8 and as a temporary skin
substitute.9 The material has also been investigated as
a scaffold for the tissue engineering of cartilage.10 To our
knowledge, BC is neither widely used nor investigated for
tissue-engineering applications. This study aimed to




A. xylinum produces cellulose in a highly swollen form,
using glucose as the carbon source (SchrammeHestrin
mediumd). The water-absorption capacity was between 100
and 120 times over its dry weight. Solely, one BC graft could
be produced in a patent construction (Fig. 1) over a culti-
vation time of 10 days. The network of fine, highly entan-
gled nanofibrils with dimensions of approximately 100 nm is
seen with scanning electron microscopy (SEM) (Fig. 2). For
this study, the process created moist tubes with a length of
about 10 mm, an internal diameter of 3.0e3.7 mm and
a wall thickness of 0.6e1.0 mm. The inner diameter could
be diversified by altering the size of a glass mandrill, whichd Medium: 20 g glucose, 5 g bactopepton, 5 g barm essence,
3.4 g di-Na-hydrogenphosphat-dihydrat, 1.15 g citric acid-
monohydrate per litre of pure water.was used as the shaped body wall. The BC graft consists of
1% cellulose as the microstructure and 99% water, and this
allows room for cell in-growth and proliferation. To improve
cell in-growth, different techniques can be used to create
more free space in the BC pellicle. One method can be the
use of leaching techniques, for example, introducing
paraffin spheres during culture and then removing them by
leaching. Another way is to use cellulases, which are
enzymes that degrade cellulose and can alter the density of
the BC pellicle. For our experiment, BC was purified by
boiling in 0.1 M NaOH at 60 C for 4 h and, thereafter, the
material was steam sterilised (1 bar, 120 C) for 20 min and
stored in Ringer’s solution until required for use.
In vivo experiments of the BC graft
Eight kinds of BC grafts were provided and implanted in
juvenile, white, domestic pigs weighing between 35 and
40 kg. The study was approved by the Animal Care and Use
Committee of the FriedricheSchiller University in Jena. All
animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals as revised
by the National Institute of Health in 1985. Anaesthesia was
induced and ventilatory support was established. The
animals were heparinised systemically with an intravenous
bolus injection of 200 units kg1 and the right carotid artery
was carefully prepared (Fig. 2a). Then, the target artery
was resected and interposed with the BC graft using an
interrupted suture with 7/0 monofilament Prolene. Hae-
mostasis was easily obtained after the initial oozing through
the graft at de-clamping. To assess the patency of the
grafts, flow measurement (MediStim AS, Oslo, Norway) was
carried out at a mean blood pressure of 70 mmHg (Fig. 2b).
After wound closure, all animals were allowed to grow for
3 months. After this time interval, the animals were sacri-
ficed and the implants evaluated for aspects of chronic
inflammation, foreign-body responses, cell in-growth and
diameter, using histology and electron microscopy
(LEO 1450 VP/REM, Oberkochem-Zeiss, Germany). The
native carotid artery served as the control.
Results
All pigs survived surgery. Paraplegia was not observed in
any animal during the postoperative period. BC had good
surgical capabilities, that is, suture and handling that were
qualitatively considered to be appropriate, and flow was
restored with no leaks or oozing through the polymer after
the anastomoses were completed. There were no signifi-
cant differences in blood flow at the proximal and distal
anastomoses after the initial implantation (53.6 ml 10 ml
and 53.7 ml 8.5 ml). The patency rate of all grafts was
87.5% (one of the eight grafts was found to be occluded).
Although the grafts were covered by an adhesion capsule,
there were no stenoses observed histologically at the
proximal or distal anastomoses in any animal. There were
no apparent changes such as dilatation, dehiscence or
aneurysm formation in any of the grafts. There were no
significant differences in the implant diameter before
(3.3 mm 0.22 mm) and 90 days after the operation
(3.2 mm 0.24 mm). The occluded vessel demonstrated
Figure 1 Assembly of BC tubes.
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fied, probably due to the surrounding tissue. There was no
bleeding from the grafts or any formation of arteriovenous
fistula.
Morphological evaluations
All patent grafts revealed no significant stenoses, histo-
logically, and there was only a minimal intimal hyperplasia.
However, the macrostructure of the BC tube appeared
altered. In the haematoxylin and eosin staining, a three-
layered wall construction was observed throughout the
implanted BC tubes, which were nearly indistinguishable
from the original carotid vessel. All grafts had a single layer
of endothelium with a basement membrane and a thin layer
of collagen followed by a concentric layer of smooth muscle
and an outer layer of fibrous cells. Graft endothelialisation
was observed at the anastomosis sites and at the centre in
all the grafts. The neo-intimal thickness of the BC graft was
115 90 mm. There was no increased proliferation of
infectious cells (lymphocytes, granulocytes and macro-
phages) close to the newly formed intima and media.Figure 2 The BC graft implanted in the porcine carotid
artery (7/0 Prolene). Patency was subsequently controlled by
flow measurement. The ultra-fine network structure of cellu-
lose in the tube (inset). The matrix did not contain cells and
required no pre-clotting.However, there was a proliferation of fibroblasts. No
specific infectious cells could be found. Isolated particles of
cellulose, which cannot be metabolised by the human body,
were detected e mostly located in the new media region
(Fig. 3). These were surrounded by few lymphocytes. SEM
also revealed a homogeneous endothelialisation inside the
grafts with an almost smooth transition to the artery
(Fig. 4). The applied Elastica van Gieson staining demon-
strated the presence of collagen structure and also proved
the absence of an elastic matrix.
Discussion
There is a need to develop novel vascular grafts that
function well in small-diameter applications because small-
calibre vascular grafts are associated with high rates of
graft failure. Synthetic small-calibre grafts will require
patency equivalent to that of autologous arterial vessels.
Bioengineering innovations have enabled the seeding of
endothelial and smooth muscle cells onto synthetic
grafts.10 Although a seeded graft worked well experimen-
tally, graft preparation is time consuming and technically
difficult. If a synthetic graft has good endothelialisation
without any seeding, it would be more practical to use it
rather than a seeded graft. Further, complete incorpora-
tion into host tissues and the maintenance of a viable and
self-renewing endothelial layer are the fundamental goals
to be achieved when developing a TEBV. Sourcing of cells
and modulating their interaction with the extracellular
matrix and supporting scaffold have been the focus of
intense research. Although the use of TEBV in humans has
been limited so far, advances in our knowledge of stem cell
precursors and the development of new biomaterials should
enable this technology to reach routine clinical practice
within a decade. The biocompatibility of a scaffold for
tissue-engineered constructs is essential for the outcome.
BC consists of completely pure cellulose nanofibrils syn-
thesised by A. xylinum. The morphology of single nano-
fibrils, the network structures of BC and the stressestrain
response show similarities to that of a collagen network.11
BC has high mechanical strength and can be shaped into
three-dimensional structures. Cellulose-based materials
induce negligible foreign-body and inflammatory responses
and are considered biocompatible.12 The in vivo biocom-
patibility of BC has never been evaluated systematically.
Figure 3 Graft histology (H&E staining) at the experimental end point after 3 months. (a) An untreated segment of the carotid
artery; (b) the BC graft after 3 months representing a ‘vessel-like’ wall structure (arrows) showing a mild infiltration of lympho-
cytes; (c) cellulose fragments (arrows) are still detectable, which was not out of the ordinary as cellulose is non-degradable in the
human organism.
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with a BC scaffold, it is necessary to evaluate the in vivo
biocompatibility. In the present study, short BC grafts were
implanted in the carotid artery of pigs for 12 weeks. The
tubes demonstrated an acceptable patency rate (87.5%)
with no signs of thrombosis and showed good in situ tissue
regeneration for up to 3 months without excessive neo-
intimal hyperplasia or aneurysm formation. Histologically,
BC grafts had a three-layered structure, which was remi-
niscent of the natural arterial structure. The luminal wall of
the newly formed tissue (particularly the intima) showed
complete endothelialisation with a confluent endothelial
layer. There were no macroscopic signs of inflammation
around the implants. There were only mild microscopic
signs of inflammation around the non-degradable cellulose
particles. No fibrotic capsule or giant cells were present.
Fibroblasts infiltrated BC, which was well integrated into
the host tissue. However, there was a proliferation of
fibroblasts, which could be considered a chronic form of
infection, although no specific infectious cells could be
found. Instead of collagen, the absence of elastic fibres was
observed in the neo-tissue. Further biomechanical exami-
nation has to be undertaken to demonstrate whether the
pliability of the regenerated BC graft can increase to the
same level as that of the native artery.
In this study, the precise mechanisms behind in situ
regeneration have not been evaluated. In our opinion,
there could be two possible reasons for this regeneration.Figure 4 SEM (magnification 16e19) revealed a good endothelia
the carotid artery.First, the graft macrostructure itself supplies a scaffold for
endothelialisation, and cellular infiltration may be origi-
nating from the circulating blood or, second, the graft
becomes completely incorporated with the host tissue by
the infiltration of cells from both anastomotic sites. If
endothelial cells inside the graft come only from the
anastomotic sites, the BC graft may have a limited critical
graft length that reduces its clinical availability. For the
next step, we consider the production of longer grafts
(up to 10 cm) for use in the grafting procedures.
The degradation of BC has not been fully evaluated in
either an in vitro or an in vivo setting. Other cellulose-
based materials have, however, shown limited degrada-
tion.13 The idea of a completely degradable material for
TEBV is very attractive. In reality, however, problems with
degradable materials are clearly present, but are often
neglected. Widely used polymers, such as polyglycolic acid
(PGA) and polylactic acid (PLA), yield degradation products
that, both chemically and mechanically, inhibit cell
proliferation in vitro and induce inflammatory reactions in
vivo.14 However, so far, there is no completely biodegrad-
able small-diameter graft suitable for use in the arterial
circulation in humans. The transportation of waste prod-
ucts from resorbed polymers is an important concern. The
degradation of the material by the cells would be desirable,
but it is difficult to optimise and synchronise the degrada-
tion time and mechanical properties of polymers. Keeping
these difficulties associated with the use of the degradablelisation of the BC grafts (b and c). (a) An untreated segment of
596 J. Wippermann et al.scaffold in mind, a non-degradable, biocompatible scaffold
that supports cell adhesion, proliferation and migration
would be a major therapeutic advance.
Limitations of the study
This study is a very preliminary evaluation of a novel, bio-
engineered, synthetic, small-calibre BC graft. Since grafts
were examined for histology alone, no biomechanical
properties or hydrodynamics studies at several different
time points were performed. The graft compliance and
tensile strength will likely continue to change as the graft
becomes completely incorporated with the host tissue.
Once the process of graft remodelling is completed, the
conduit could reach a stable condition in which its
mechanical properties will become equivalent to that of
the normal tissue over time. There was histological
evidence that the macrostructure (trapped water) was
degrading during 12 weeks, so we conclude that the
microstructure is primarily responsible for the fluctuations
in the biomechanical stability of the graft over time.13
A long-term study is currently being conducted to evaluate
changes in the biomechanical stability of the graft.
Conclusion
This preliminary work demonstrates that it will be possible
to rapidly fabricate a polymeric tubular graft in vitro and to
implant it as a substitute for a small-diameter artery. BC
promotes in situ vascular tissue regeneration and does not
require pre-treatment in the form of cell seeding. Thus, BC
exhibits properties that are promising for its further use in
TEBV programmes.
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